|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
This is an open label clinical study to evaluate the activity of chloroquine phosphate in patients with SARS-CoV-2 virus infection. The study aims to document possible prevention of pneumonia in patients staying at home and in improving the symptoms of SARS-CoV-2 pneumonia in patients who will be hospitalised.
Description: Achieving 50% reduction in symptom score for patients with lower respiratory tract infection on day 8 visit from study initiation.Measure: 50% reduction in symptom score for patients with lower respiratory tract infection Time: Day 8 visit from study initiation
Description: Lack of progression to lower respiratory tract infection in patients enrolled in the study due to upper respiratory tract infection on day 8 visit from study initiation.Measure: Lack of progression for patients with upper respiratory tract infection Time: Day 8 visit from study initiation
Description: Lower respiratory tract infection rating takes place. The symptoms checked are: Cough, Chest pain, Dyspnea, expectoration. For each symptom score is given from 0 to 3 depending on the intensity and they are summed.Measure: Comparison of the primary endpoint with respective patients not receiving the treatment Time: Day 14 visit from study initiation
Description: It is defined as the presence of both of the following: Respiratory quotient (pO2 / FiO2) less than 150 Need for treatment with CPAP or mechanical ventilationMeasure: Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment. Time: Day 14 visit from study initiation
Description: Frequency of AEs and SAEsMeasure: Frequency of AEs and SAEs Time: Day 14 visit from study initiation
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports